Annual Non Current Assets
$215.56 M
+$84.09 M+63.96%
December 31, 2023
Summary
- As of February 7, 2025, RXRX annual long term assets is $215.56 million, with the most recent change of +$84.09 million (+63.96%) on December 31, 2023.
- During the last 3 years, RXRX annual non current assets has risen by +$183.41 million (+570.53%).
- RXRX annual non current assets is now at all-time high.
Performance
RXRX Non Current Assets Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Non Current Assets
$252.33 M
-$1.16 M-0.46%
September 30, 2024
Summary
- As of February 7, 2025, RXRX quarterly long term assets is $252.33 million, with the most recent change of -$1.16 million (-0.46%) on September 30, 2024.
- Over the past year, RXRX quarterly non current assets has increased by +$38.09 million (+17.78%).
- RXRX quarterly non current assets is now -0.46% below its all-time high of $253.49 million, reached on June 30, 2024.
Performance
RXRX Quarterly Non Current Assets Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Non Current Assets Formula
Non Current Assets = Property, Plant, and Equipment + Intangible Assets + Long-Term Investments + Deferred Tax Assets + Other Non-Current Assets
RXRX Non Current Assets Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +64.0% | +17.8% |
| 3 y3 years | +570.5% | +91.9% |
| 5 y5 years | +761.1% | +91.9% |
RXRX Non Current Assets Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +185.0% | -0.5% | +233.7% |
| 5 y | 5-year | at high | +761.1% | -0.5% | +684.9% |
| alltime | all time | at high | +761.1% | -0.5% | +684.9% |
Recursion Pharmaceuticals Non Current Assets History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $252.33 M(-0.5%) |
| Jun 2024 | - | $253.49 M(+18.3%) |
| Mar 2024 | - | $214.23 M(-0.6%) |
| Dec 2023 | $438.14 M(-23.1%) | $215.56 M(-2.2%) |
| Sep 2023 | - | $220.30 M(-6.5%) |
| Jun 2023 | - | $235.68 M(+74.3%) |
| Mar 2023 | - | $135.24 M(+2.9%) |
| Dec 2022 | $569.81 M | $131.47 M(+1.2%) |
| Sep 2022 | - | $129.91 M(+2.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $126.52 M(+10.1%) |
| Mar 2022 | - | $114.86 M(+51.9%) |
| Dec 2021 | $534.72 M(+100.7%) | $75.63 M(+31.0%) |
| Sep 2021 | - | $57.74 M(+13.3%) |
| Jun 2021 | - | $50.95 M(+1.7%) |
| Mar 2021 | - | $50.12 M(+55.9%) |
| Dec 2020 | $266.44 M(+248.7%) | - |
| Dec 2020 | - | $32.15 M |
| Dec 2019 | $76.40 M | - |
FAQ
- What is Recursion Pharmaceuticals annual long term assets?
- What is the all time high annual non current assets for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual non current assets year-on-year change?
- What is Recursion Pharmaceuticals quarterly long term assets?
- What is the all time high quarterly non current assets for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly non current assets year-on-year change?
What is Recursion Pharmaceuticals annual long term assets?
The current annual non current assets of RXRX is $215.56 M
What is the all time high annual non current assets for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual long term assets is $215.56 M
What is Recursion Pharmaceuticals annual non current assets year-on-year change?
Over the past year, RXRX annual long term assets has changed by +$84.09 M (+63.96%)
What is Recursion Pharmaceuticals quarterly long term assets?
The current quarterly non current assets of RXRX is $252.33 M
What is the all time high quarterly non current assets for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly long term assets is $253.49 M
What is Recursion Pharmaceuticals quarterly non current assets year-on-year change?
Over the past year, RXRX quarterly long term assets has changed by +$38.09 M (+17.78%)